Opendata, web and dolomites

TransQST SIGNED

Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TransQST" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF LIVERPOOL 

Organization address
address: BROWNLOW HILL 765 FOUNDATION BUILDING
city: LIVERPOOL
postcode: L69 7ZX
website: www.liverpool.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://transqst.org/
 Total cost 17˙327˙874 €
 EC max contribution 8˙000˙000 € (46%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-06-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) coordinator 1˙620˙350.00
2    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 1˙060˙725.00
3    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) participant 1˙026˙750.00
4    FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM ES (BARCELONA) participant 900˙525.00
5    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 675˙300.00
6    CERTARA UK LIMITED UK (LONDON) participant 450˙900.00
7    FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E.V. DE (DORTMUND) participant 350˙250.00
8    UNIVERSITAT WIEN AT (WIEN) participant 350˙250.00
9    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 341˙450.00
10    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 325˙000.00
11    OCELLO BV NL (LEIDEN) participant 275˙775.00
12    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 269˙790.00
13    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 220˙500.00
14    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 132˙435.00
15    ABBVIE DEUTSCHLAND GMBH & CO KG DE (WIESBADEN) participant 0.00
16    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
17    BOEHRINGER INGELHEIM INTERNATIONALGMBH DE (INGELHEIM) participant 0.00
18    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
19    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
20    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
21    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
22    ORION OYJ FI (ESPOO) participant 0.00
23    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.

 Publications

year authors and title journal last update
List of publications.
2017 Elisa Passini, Oliver J. Britton, Hua Rong Lu, Jutta Rohrbacher, An N. Hermans, David J. Gallacher, Robert J. H. Greig, Alfonso Bueno-Orovio, Blanca Rodriguez
Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity
published pages: , ISSN: 1664-042X, DOI: 10.3389/fphys.2017.00668
Frontiers in Physiology 8 2019-10-15
2017 Elaina M. Maldonado, Vytautas Leoncikas, Ciarán P. Fisher, J. Bernadette Moore, Nick J. Plant, Andrzej M. Kierzek
Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics
published pages: 732-746, ISSN: 2163-8306, DOI: 10.1002/psp4.12230
CPT: Pharmacometrics & Systems Pharmacology 6/11 2019-10-15
2018 Terezinha Souza, Panuwat Trairatphisan, Janet Piñero, Laura I. Furlong, Julio Saez-Rodriguez, Jos Kleinjans, Danyel Jennen
Embracing the Dark Side: Computational Approaches to Unveil the Functionality of Genes Lacking Biological Annotation in Drug-Induced Liver Injury
published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00527
Frontiers in Genetics 9 2019-10-15
2018 Manuel Pastor, Jordi Quintana, Ferran Sanz
Development of an Infrastructure for the Prediction of Biological Endpoints in Industrial Environments. Lessons Learned at the eTOX Project
published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2018.01147
Frontiers in Pharmacology 9 2019-10-15
2018 Janet Piñero, Abel Gonzalez-Perez, Emre Guney, Joaquim Aguirre-Plans, Ferran Sanz, Baldo Oliva, Laura I. Furlong
Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response
published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00412
Frontiers in Genetics 9 2019-10-15
2019 Ian M. Copple, Wouter den Hollander, Giulia Callegaro, Fiona E. Mutter, James L. Maggs, Amy L. Schofield, Lucille Rainbow, Yongxiang Fang, Jeffrey J. Sutherland, Ewa C. Ellis, Magnus Ingelman-Sundberg, Stephen W. Fenwick, Christopher E. Goldring, Bob van de Water, James L. Stevens, B. Kevin Park
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury
published pages: 385-399, ISSN: 0340-5761, DOI: 10.1007/s00204-018-2354-1
Archives of Toxicology 93/2 2019-10-15
2018 Anyue Yin, Akihiro Yamada, Wiro B Stam, Johan G C van Hasselt, Piet H van der Graaf
Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction
published pages: 3394-3406, ISSN: 0007-1188, DOI: 10.1111/bph.14385
British Journal of Pharmacology 175/16 2019-10-15
2018 Janet Piñero, Laura I Furlong, Ferran Sanz
In silico models in drug development: where we are
published pages: 111-121, ISSN: 1471-4892, DOI: 10.1016/j.coph.2018.08.007
Current Opinion in Pharmacology 42 2019-10-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSQST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSQST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More